Current and future management of Ph/BCR-ABL positive ALL

References

• Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991;78(9):2411-18
   PubMed Web of Science ®Google Scholar
• Cimino G, Pane F, Elia L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica 2006;91(3):377-80
   PubMed Web of Science ®Google Scholar
• Tabernero MD, Bortoluci AM, Alaejos I, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia 2001;15(3):406-14
   PubMed Web of Science ®Google Scholar
• Anastasi J, Feng J, Dickstein JI, et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia 1996;10(5):795-802
   Google Scholar
• Schenk TM, Keyhani A, Bottcher S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998;12(5):666-74
   Google Scholar
• Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99(5):1536-43
   PubMed Web of Science ®Google Scholar
• Haferlach T, Winkemann M, Ramm-Petersen L, et al. New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol 1997;99(2):452-9
   Google Scholar
• Rieder H, Ludwig WD, Gassmann W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996;95(4):678-91
   Google Scholar
• Wetzler M, Dodge RK, Mrozek K, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 2004;124(3):275-88
   Google Scholar
• Yanada M, Takeuchi J, Sugiura I, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008;93(2):287-90
   Google Scholar
• Rousselot P, Cayuela J-M, Recher C, et al. Dasatinib (Sprycel(R)) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 trial (on Behalf of the European Working Group on Adult ALL (EWALL)). ASH Annual Meeting Abstracts 2008;112(11):2920
   Google Scholar
• Hofmann WK, de Vos S, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002;359(9305):481-6
   PubMed Web of Science ®Google Scholar
• Juric D, Lacayo NJ, Ramsey MC, et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 2007;25(11):1341-9
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360(5):470-80
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112(9):3847-55
   PubMed Web of Science ®Google Scholar
• Collins-Underwood JR, Mullighan CG. Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia 2010;24(10):1676-85
   Google Scholar
• Ramakers-van Woerden NL, Pieters R, Hoelzer D, et al. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 2002;38(6):379-86
   Google Scholar
• Rieder H, Bonwetsch C, Janssen LA, et al. High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia. Leukemia 1998;12(9):1473-81
   Google Scholar
• Maurer J, Thiel E, Ludwig W-D, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991;337(8749):1055-8
   PubMed Web of Science ®Google Scholar
• Radich JP, Kopecky KJ, Boldt DH, et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994;8(10):1688-95
   Google Scholar
• Gleissner B, Rieder H, Thiel E, et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data. Leukemia 2001;15(12):1834-40
   PubMed Web of Science ®Google Scholar
• Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997;89(7):2602-9
   Google Scholar
• Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) during imatinib treatment. Leukemia 2003;17(9):1700-6
   Google Scholar
• Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. a collaborative study of the Group Francais de Cytogenetique Hematologique. Blood 1996;87(8):3135-42
   PubMed Web of Science ®Google Scholar
• Bassan R, Rohatiner AZ, Lerede T, et al. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. Hematol J 2000;1(4):226-34
   Google Scholar
• Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000;36(3-4):263-73
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trial. Blood 2002;100(7):2357-66
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009;113(19):4489-96
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992;79(11):3067-70
   Google Scholar
• Chao NJ, Blume KG, Forman SJ, Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995;85(11):3353-4
   Google Scholar
• Snyder DS, Nademanee AP, O’Donnell MR, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999;13(12):2053-8
   Google Scholar
• Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998-1006
   PubMed Web of Science ®Google Scholar
• Goldstone A, Prentice HG, Durrant IJ. Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2993). Blood 2001;98:Abstract 856a
   Google Scholar
• Esperou H, Boiron JM, Cayuela JM, et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003;31(10):909-18
   Google Scholar
• Schrappe M, Aricò M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92(8):2730-41
   Google Scholar
• Roy A, Bradburn M, Moorman AV, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005;129(1):35-44
   Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-42
   PubMed Web of Science ®Google Scholar
• Karamlou K, Grant C, Maziarz RT. Kinetics of response to Gleevec in chronic myelogenous leukemia blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia patients. Blood 2001;98:590a
   Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100(6):1965-71
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood 2004;103(4):1495-8
   Google Scholar
• Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002;16(12):2358-65
   PubMed Web of Science ®Google Scholar
• Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006;20(3):400-3
   PubMed Web of Science ®Google Scholar
• Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96(9):3195-9
   PubMed Web of Science ®Google Scholar
• Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96(6):2246-53
   Web of Science ®Google Scholar
• Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002;16(12):2349-57
   Google Scholar
• Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002;119(1):3-14
   Google Scholar
• Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19(9):1509-16
   Google Scholar
• Thomas DA, Kantarjian HM, Cortes J, et al. Outcome after frontline therapy with the hyper-CVAD and Imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 2008;112(11):2931
   Google Scholar
• Hatta Y, Mizuta S, Ohtake S, et al. Promising outcome of imatinib-combined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 Regimen. ASH Annual Meeting Abstracts 2009;114(22):3090
   Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy leukemia group protocol 09/00. J Clin Oncol 2010;28(22):3644-52
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). ASH Annual Meeting Abstracts 2010;116(21):173
   Google Scholar
• Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010;95(1):87-95
   PubMedGoogle Scholar
• Ribera JM, Garcia O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 2012;159(1):78-81
   PubMed Web of Science ®Google Scholar
• Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant 2013;19(1):150-5
   PubMed Web of Science ®Google Scholar
• Thyagu S, Minden MD, Gupta V, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. Br J Haematol 2012;158(4):506-14
   Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) treated with high-dose imatinib? Results of the Prospective Randomized Graaph-2005 Study. ASH Annual Meeting Abstracts 2012;120(21):138
   Google Scholar
• Fielding AK, Rowe J, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive Acute Lymphoblastic Leukaemia. Blood 2014;123(6):843-50
   PubMed Web of Science ®Google Scholar
• Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012;13(9):936-45
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109(9):3676-8
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007;109(10):2068-76
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110(7):2309-15
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357(15):1557; author reply 1557-1558
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosoma positive acute lymphoblastic leukemia. Blood 2011;118(25):6521-8
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Garris R, et al. Final report of single-center study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia. ASH Annual Meeting Abstracts 2013; In press
   Google Scholar
• Kim DY, Don Joo Y, Kim SD, Lee KH. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: final results of prospective multicenter phase 2 study. ASH Annual Meeting Abstracts 2013; In press
   Google Scholar
• Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 2013;54(1):21-7
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Thomas D, et al. Phase II study of combination of Hyper-CVAD with Ponatinib in front line therapy of patients (pts) with Philadelphia chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL). J Clin Oncol 2013;31(Suppl):Abstract 7024
   Google Scholar
• Mitterbauer G, Nemeth P, Wacha S, et al. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 1999;106(3):634-43
   Google Scholar
• Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005;19(4):628-35
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396-407
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005;106(2):458-63
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108(5):1469-77
   PubMed Web of Science ®Google Scholar
• Lee S, Kim YJ, Chung NG, et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2009;115(3):561-70
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116(12):2070-7
   PubMed Web of Science ®Google Scholar
• Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012;26(11):2367-74
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coude MM, Huguet F, et al. Dasatinib (Sprycel(R)) and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 Study. ASH Annual Meeting Abstracts 2012;120(21):666
   Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013;122(7):1214-21
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007;92(5):612-18
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110(2):727-34
   PubMed Web of Science ®Google Scholar
• Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011;96(4):552-7
   Google Scholar
• Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012;26(7):1475-81
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008;113(5):985-94
   PubMedGoogle Scholar
• Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011;25(1):41-7
   Web of Science ®Google Scholar
• Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010;116(22):4439-43
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96(8):1113-20
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011;118(20):5697-700
   PubMed Web of Science ®Google Scholar
• Benjamini O, Kantarjian H, O’Brien S, et al. Combination chemotherapy with tyrosine kinase inhibitors can overcome Bcr-Abl mutation in acute lymhoblastic leukemia or blast crisis CML. ASH Annual Meeting Abstracts 2013; In press
   Google Scholar
• Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003;17(2):290-7
   Google Scholar
• Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013;27(6):1254-62
   PubMed Web of Science ®Google Scholar
• Carella AM, Frassoni F, Pollicardo N, et al. Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 1995;89(3):535-8
   Google Scholar
• Atta J, Martin H, Bruecher J, et al. Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996;18(3):541-8
   Google Scholar
• Mizuta S, Kohno A, Morishita Y, et al. Long-term follow-up of 14 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. Int J Hematol 2007;85(2):140-5
   Google Scholar
• Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer 2014;50(2):411-17
   PubMed Web of Science ®Google Scholar
• Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation – results of CALGB Study 10001 (Alliance). Haematologica 2014;99(1):111-15
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wystub S, Binckebanck A, et al. Imatinib (IM) and interferon-alpha (IFN-a) maintenance therapy is associated with long-term DFS in a subset of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). ASH Annual Meeting Abstracts 2012;120(21):1503
   Google Scholar
• Pfeifer H, Wettner C, Wassmann B, et al. Long term follow-up of 121 elderly patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL) treated in prospective GMALL trials supports a greater emphasis on allogeneic SCT as definitive postremission therapy. ASH Annual Meeting Abstracts 2012;120:21-2608
   Google Scholar
• Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006;20(9):1526-32
   PubMed Web of Science ®Google Scholar
• Papayannidis C, Fazi P, Piciocchi A, et al. Treating Ph+ acute lymphoblastic leukemia (ALL) in the elderly: the sequence of two tyrosine kinase Inhibitors (TKI) (Nilotinib and Imatinib) does not prevent mutations and relapse. ASH Annual Meeting Abstracts 2012;120(21):2601
   Google Scholar
• Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9(13):4674-81
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O’Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119(1):106-8
   PubMed Web of Science ®Google Scholar
• Patel SB, Gojo I, Tidwell ML, et al. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52(7):1211-14
   PubMed Web of Science ®Google Scholar
• Bassan R. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era? Leuk Lymphoma 2011;52(7):1164-5
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hartog CM, Bassan R, et al. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica 2011;96(2):238-44
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112(4):1005-12
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14(6):e205-17
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27(1):107-12
   PubMed Web of Science ®Google Scholar
• Katagiri S, Tauchi T, Okabe S, et al. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res 2013;19(6):1422-32
   PubMed Web of Science ®Google Scholar
• Riva G, Luppi M, Barozzi P, et al. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood 2010;115(8):1512-18
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012;26(1):25-32
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Wayne AS, O’Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012;30(31):3876-83
   PubMed Web of Science ®Google Scholar
• Bassan R, Scattolin AM, Maino E, et al. Monoclonal antibody therapy of adult acute lymphoblastic leukemia: progress and challenge for new clinical trials. Drugs Cell Ther Hematol 2013;1(1):5-20
   Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119(15):2728-36
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
   PubMed Web of Science ®Google Scholar
• Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 2012;120(21):670
   Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra138
   Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2012;121(7):1165-74
   Google Scholar
• Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122(17):2965-73
   PubMed Web of Science ®Google Scholar